TQB-3823

N/A

Report date: 2025/04/21 20:01:10
NME

Base Information

Drug NameTQB-3823
Drug Alias NameTQB-3823
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) Polymerase 2 inhibitorsPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1Poly (ADP-Ribose) Polymerase 2
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantFallopian Tube Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian Neoplasms
Inactive IndicationsProstatic Neoplasms, Castration-ResistantFallopian Tube NeoplasmsPeritoneal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A